#United Kingdom #Oxford #Prostate Cancer #Blue Earth #Lutetium

Introduction

Blue Earth Therapeutics has recently advanced the field of cancer treatment with its promising findings from the Phase 1 clinical trials of Lutetium (177Lu) rhPSMA-10.1 Injection. This investigational therapy, designed specifically for metastatic prostate cancer, harnesses the power of radiation to deliver targeted treatment effectively.

Clinical Overview

During the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), held in June 2025, the results were unveiled by a team from Radboud University Medical Centre, with Professor James Nagarajah leading the presentation. The trial analyzed radiation dosimetry results from 34 treatment cycles involving 13 patients with metastatic castrate-resistant prostate cancer.

The findings revealed significant insights into how the therapy delivers radiation doses to tumors compared with normal organs. Specifically, the mean absorbed dose to tumors was impressively high at 8.87 Gy/GBq, while doses to kidneys and salivary glands were markedly lower, at 0.30 Gy/GBq and 0.13 Gy/GBq, respectively. These results yielded a tumor-to-kidney ratio of 32.09 and a tumor-to-salivary gland ratio of 73.19, demonstrating the therapy's potential effectiveness and relative safety.

Methodology

The study employed advanced tumor dosimetry methodologies, utilizing PET and SPECT scans to pinpoint lesions for evaluation. This innovative approach aligns with established techniques documented in existing literature for other radioligand therapies. Furthermore, a unique "anatomy-based" dosimetry evaluation assessed tumor volumes based solely on CT scans conducted by blinded radiologists. This methodology captured all tumor regions regardless of drug uptake, providing a comprehensive view of the therapeutic efficacy.

Future Implications

David Gauden DPhil, CEO of Blue Earth Therapeutics, expressed optimism about the findings: “Numerous studies across various cancer types have shown the therapeutic value of delivering high radiation doses to tumors. The Phase 1 dosimetry data being presented is a notable validation of the concept that improved agents are possible.” He further elaborated that ongoing Phase 2 studies will explore administering larger doses of radioactivity during early treatment cycles, potentially amplifying therapeutic benefits.

Background on Prostate Cancer

Prostate cancer remains a significant health challenge, particularly with projections indicating over 50,000 new cases in the U.S. in 2025. Despite advances in treatment, the five-year survival rate for men diagnosed with metastatic prostate cancer stands at a concerning 36.6%. The need for better therapeutic options is clear, and breakthroughs like that of Blue Earth Therapeutics' innovative therapy may pave the way for improved patient survival rates and quality of life.

Conclusion

Blue Earth Therapeutics is positioned at the forefront of developing targeted radiotherapeutics that promise to revolutionize treatment for advanced prostate cancer. With a dedicated focus on harnessing the therapeutic capabilities of rhPSMA compounds, the company is expanding its research to yield safer and more effective interventions in the battle against cancer. The upcoming phases of clinical trials will be critical in determining how these findings translate into effective treatments for patients undergoing similar struggles.

For more information on Blue Earth Therapeutics and its emerging treatments, please visit their official website.